Humana Inc. (NYSE:HUM – Get Rating) insider Samir Deshpande sold 3,957 shares of the company’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $434.19, for a total transaction of $1,718,089.83. Following the sale, the insider now directly owns 5,529 shares in the company, valued at $2,400,636.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of HUM opened at $442.34 on Thursday. The firm has a market cap of $55.95 billion, a P/E ratio of 18.77, a P/E/G ratio of 1.28 and a beta of 0.86. The stock has a 50 day simple moving average of $441.77 and a two-hundred day simple moving average of $435.25. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. Humana Inc. has a 1 year low of $351.20 and a 1 year high of $475.44.
Humana (NYSE:HUM – Get Rating) last issued its earnings results on Wednesday, April 27th. The insurance provider reported $8.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $6.79 by $1.25. The business had revenue of $23.97 billion during the quarter, compared to analyst estimates of $23.54 billion. Humana had a return on equity of 17.27% and a net margin of 3.51%. Humana’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $7.67 earnings per share. On average, equities analysts anticipate that Humana Inc. will post 24.65 earnings per share for the current year.
Several equities research analysts have commented on HUM shares. SVB Leerink dropped their price objective on shares of Humana from $528.00 to $525.00 and set an “outperform” rating on the stock in a report on Thursday, February 3rd. Barclays dropped their price objective on shares of Humana from $540.00 to $490.00 and set an “overweight” rating on the stock in a report on Friday, January 7th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Humana from $418.00 to $435.00 in a report on Thursday, February 3rd. Zacks Investment Research upgraded Humana from a “sell” rating to a “hold” rating and set a $445.00 price target on the stock in a research report on Friday, February 4th. Finally, Morgan Stanley upped their price target on Humana from $410.00 to $436.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 9th. Seven analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humana currently has an average rating of “Buy” and an average target price of $486.28.
Institutional investors and hedge funds have recently modified their holdings of the business. Bell Investment Advisors Inc purchased a new stake in Humana in the third quarter worth approximately $26,000. Spire Wealth Management purchased a new stake in shares of Humana during the fourth quarter valued at approximately $30,000. BerganKDV Wealth Management LLC boosted its stake in shares of Humana by 885.7% during the fourth quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 62 shares during the period. Riverview Trust Co purchased a new stake in shares of Humana during the first quarter valued at approximately $32,000. Finally, Selective Wealth Management Inc. purchased a new stake in shares of Humana during the fourth quarter valued at approximately $35,000. 94.93% of the stock is owned by institutional investors and hedge funds.
About Humana (Get Rating)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.